Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT07252232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07252232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
December 15, 2025
Completion date
July 10, 2030
Enrollment
500 (estimated)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pdac, pdac - pancreatic ductal adenocarcinoma, resectable pancreatic ductal adenocarcinoma (pdac), resected pancreatic adenocarcinoma